anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
###  Renal Toxicity

Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. 

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics, ACE inhibitors or the ARBs, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.

No information is available from controlled clinical studies regarding the use of CELEBREX in patients with advanced renal disease. The renal effects of CELEBREX may hasten the progression of renal dysfunction in patients with preexisting renal disease. 

Correct volume status in dehydrated or hypovolemic patients prior to initiating CELEBREX. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use of CELEBREX [see Drug Interactions (7)]. Avoid the use of CELEBREX in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function. If CELEBREX is used in patients with advanced renal disease, monitor patients for signs of worsening renal function.

###  Hyperkalemia

Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.
PURPOSE: A composition for skin whitening containing a material which suppresses expression or activation of alpha-synuclein gene is provided to ensure skin whitening activity without citotoxicity. CONSTITUTION: A composition for skin whitening contains a material which suppresses expression or activation of alpha-synuclein gene. A pharmaceutical composition for skin whitening contains the composition. The alpha-synuclein gene encodes alpha-synuclein protein with an amino acid sequence of sequence number 1. The alpha-synuclein gene has a base sequence of sequence number 2. The material is an antibody or antibody fragment which specifically binds to the protein.
Cervical cancer is the second most common cancer among women globally and the most prevalent cancer in developing countries, which was caused by human papillomavirus (HPV) infection. Messenger RNA (mRNA) vaccines have opened up new avenues for vaccine development and pandemic preparedness with potent scalability, which may possess the potential antitumor effects of an mRNA-HPV therapeutic vaccine containing nononcogenic E6 and E7 proteins. Here, we reported a lipid nanoparticle (LNP) plus nucleic acid immunostimulators (CPG 1018 and Poly I:C) mRNA vaccine platform. The LNP-CPG 1018 capsulated HPV E6-E7 mRNA significantly promoted the maturation of bone marrow-derived dendritic cells (BMDC) in vitro and were capable of efficiently migrating to lymph nodes (LN) in vivo. In TC-1 tumor-bearing mice, the subcutaneous immunization of LNP-CPG 1018 capsulated HPV E6-E7 mRNA elicited robust tumor-specific T-cell immunity, reshaped the tumor microenvironment, and inhibited tumor growth. In conclusion, the LNP-CPG 1018 system is a promising delivery platform for facilitating the development of HPV E6-E7 mRNA cancer vaccines.
Mitral stenosis is the most common rheumatic heart disease (RHD) disorder worldwide, including in Indonesia. This pathological condition causes left atrial pressure, leading to left atrial fibrosis that affects the structure and function of the left atrial as well as the clinical condition. The aim of this study was to assess the correlation between circulating fibrosis biomarkers with net atrioventricular compliance (Cn) as a parameter of left atrial function, and left atrial volume index (LAVI) as a parameter left atrium structure of changes. A cross-sectional study was conducted at Panti Rahayu Hospital and Permata Bunda Hospital, Purwodadi, Central Java, with a total of 40 RHD patients with severe mitral stenosis. The ELISA was used to measure the levels of carboxy-terminal propeptide of type I procollagen (PICP), matrix metalloproteinase I (MMP-1), tissue inhibitor matrix metalloproteinase 1 (TIMP-1), and transforming growth factor-β1 (TGF-β1). The left atrial function was assessed by measuring Cn, and the LAVI parameters were measured to assess left atrium structure/size. The mean levels of circulating fibrosis biomarkers were as follows: PICP 153.96±89.12 ng/mL; MMP-1 1.44±2.12 ng/mL; MMP-1/TIMP-1 ratio 0.38±0.54 and TGF-β1 2.66±1.96 pg/mL. From the echocardiographic evaluation, the mean Cn was 5.24±1.93 mL/mmHg and the mean LAVI was 152.55±79.36 mL/m2. There were significant correlation between MMP-1 and MMP-1/TIMP-1 ratio with Cn (r=0.345 and r=0.333, respectively; both had p<0.05). PICP and TGF-β1 biomarkers did not significantly correlate with Cn (p>0.05). Meanwhile, none of the biomarkers had a significant correlation with LAVI (p>0.05). This study highlights that MMP-1 and MMP-1/TIMP-1 ratio are potentially to be used as markers to determine the Cn in RHD patients with severe mitral stenosis. However, further studies with a higher sample size are needed to confirm this finding.
FIELD: medicine. SUBSTANCE: invention relates to methods of treatment of patients with infectious-septic diseases with the secondary immunodeficiency. To patients with carditis of different etiology and heart failure and concomitant chronic sepsis the following drugs are administrated for 10 days: ceruloplasmin at the dose 1.5 mg/kg every other day, reaferon at the dose 500000 IU by rectal route (two suppositoria per 24 h), vitamin E and tinalin at therapeutic doses. Method results to normalization of indices of an antioxidant protection and interferon status in these patients. EFFECT: enhanced effectiveness of method. 4 ex
The present invention discloses a compound ginkgo capsule. The capsule is made from ginkgo leaf extract, hawthorn extract, chrysanthemum extract and the supplementary material of starch with a conventional capsule preparing method. The present invention also discloses a better proportion and an optimal proportion for all component of the capsule and a method for extracting hawthorn extract and chrysanthemum extract. The compound ginkgo capsule of the present invention can coordinate and balance the heart, the lung, the liver, the stomach, the spleen and other organs of human bodies. The compound ginkgo capsule enlarges the efficacy of blood fat regulation, reduces serum cholesterol, triglyceride and low-density lipoprotein, and improves high-density lipoprotein. The present invention also improves the efficacy of anoxic resistance, namely that cell and neural damage can be reduced under the ischemic and the anoxic conditions of the heart or the brain.
The invention relates to animal-use enrofloxacin stomach-positioning pellets, and a preparation method thereof. The pellets are prepared through the steps that: a soft material is obtained by mixing enrofloxacin hydrochloride, microcrystalline cellulose, hydroxypropyl methyl cellulose, and saccharin; the soft material is prepared into micro-pellets by using a micro-pellet machine; a polymethacrylic resin latex solution is prepared into coatings; and granulation and drying are carried out, such that the stomach-positioning pellets are prepared. The pellets have good treatment effect against livestock and poultry influenza, and especially have substantial treatment effect in treating swine flu respiratory diseases. With the pellets, bitterness can be covered. When the pellets are mixed in to dry feedstuff, pig eating is not affected. A 2h accumulated dissolution rate of the pellets prepared after coating in gastric juice is 99.84%. The pellets are safe and reliable, and have the advantages of fast release, convenient application.
PURPOSE:To prevent the reaggregation of an aq. component at the outlets of the pores in a porous membrane or partition wall and to prepare a high quality water-in-oil type emulsion by pressurizing and introducing an aq. medium into an oil phase through the membrane or partition wall irradiated with ultrasonic waves. CONSTITUTION:An aq. medium and an oil phase (a hydrophobic solvent contg. a surfactant) are separately poured into chambers divided with a porous membrane or partition wall. The aq. medium is pressurized and introduced into the oil phase through the membrane or partition wall irradiated with ultrasonic waves and the oil phase is emulsified to prepare a water-in-oil type emulsion. By the action of the ultra sonic waves, the breaking and reaggregation of fine drops of an aq. component passing through the porous membrane or partition wall are prevented and the fine drops are simply separated from the surface of the membrane or partition wall and efficiently dispersed in the oil phase. This method is utilized to prepare emulsion products for chemical industry, food industry, cosmetic industry, etc.
Osteosarcoma (OS) is the most frequent primary malignant bone tumor among children and adolescents, with a peak of incidence in the second decade of life. The presence of metastasis at diagnosis in OS patients significantly decreases the chances of survival and new therapy approaches are needed. The IGFBP5 gene is related to osteoblasts metabolism and some studies have pointed out a role of its low expressions in OS development and metastasis. In this study, we aimed to establish an IGFBP5 gene expression profile among metastatic and non-metastatic OS patients throughout the treatment and development of the disease. Fresh-frozen tumor samples were obtained from 40 patients admitted to treatment at the Pediatric Oncology Institute (IOP/GRAACC/UNIFESP) and divided by clinical status: metastatic or non-metastatic disease. For each patient, samples before and after chemotherapy treatment were obtained, as well as metastasis and lung tissue surrounding metastasis samples from the metastatic patients. A quantitative real-time PCR was used to investigate IGFBP5 expression. Our analyses demonstrate that non-metastatic patients presented lower IGFBP5 expression in their pre-chemotherapy samples compared with metastatic patients, suggesting that low expressions of this gene could help triggering the OS tumorigenesis but that its action alone is not sufficient to activate the metastatic process. Heterogeneity in IGFBP5 expressions within groups was also seen. We observed that IGFBP5 and two MAPK genes, a downstream pathway in the IGFBP5 axis, are differentially expressed in OS samples of non-metastatic patients. Further investigation about these genes' modulations might lead to a better understanding of metastasis development in OS.
OBJECTIVE: Navigating obstacles involves adjusting walking patterns, particularly when stepping over them. This task may be particularly challenging for people with Parkinson disease (PD) for several reasons. This review aims to compare the spatiotemporal gait parameters of people with and without PD while stepping over obstacles.
LITERATURE SURVEY: A systematic literature search was conducted in six databases (PubMed, Scopus, Web of Science, EBSCO, Embase, and SciELO) from inception to September 2023.
METHODOLOGY: Studies were selected that evaluated gait parameters of people with and without PD while walking over obstacles. Two independent researchers evaluated the eligibility and extracted gait parameters during obstacle crossing. The risk of bias was assessed using the Joanna Briggs Institute Critical Appraisal Checklist. Heterogeneity was assessed using I2-tests. Random effects models were determined for effect sizes as standardized mean differences (SMD).
SYNTHESIS: Twenty-five studies were included in the review and 17 in the meta-analysis. Most of the studies (58%) showed a low risk of bias. People with PD exhibit a shorter step when landing after crossing an obstacle (SMD = -0.50 [-0.69 to -0.31]). Compared to people without PD, people with PD also widen their support base (SMD = 0.27 [0.07-0.47]) and reduce gait velocity (SMD = -0.60 [-0.80 to -0.39]) when crossing the obstacle.
CONCLUSIONS: People with PD adopt a more conservative motor behavior during obstacle crossing than those without PD, with a shorter step length when landing after crossing an obstacle, greater step width and lower crossing speed.
After participants are screened for inclusion, serum samples will be collected for the analysis of C-reactive protein (CRP; mg/L), rheumatoid factor (RF; UI/mL) and anti-citrullinated protein antibodies (ACPAs; UI/mL) in a reference laboratory. A complete periodontal chart will be carried out at six sites per tooth excluding third molars by a single experienced clinician using a calibrated probe (Hu-Friedy Mfg. Co.). Subgingival plaque samples will be collected by means of paper points inserted to the bottom of the pocket and processed immediately for culture analysis and detection of Porphyromonas gingivalis. RA patients will be examined by an experienced rheumatologist to determine their Disease Activity Score (DAS-28). All examinations will be taken at baseline and repeated 3 months after intervention.

Non-surgical periodontal therapy (NSPT) will be administered on the following 5 days of inclusion. A single 1-hour session of full-mouth debridement with an ultrasonic device will be carried out in each participant under local anesthesia by an experienced clinician. After NSPT is completed, each patient will receive oral hygiene instructions and oral care pack including toothbrush and toothpaste (toothbrush Vitis Encias Medium; Toothpaste Vitis Encias; Dentaid, Colombia).

Demographic ,clinical history as well as medication data for all participants will be collected. Periodontal parameters of PD (mm), PAL (mm) and BOP (%) will be recorded at each visit. The stage and grade of periodontitis will be established according to the new classification of periodontal diseases (Papapanou et al. 2018). The clinician who records data will not be blinded to the condition of the patients.

Sample size was calculated to detect a 50 % change in CRP with a power of \>80% (alpha 0,05) which resulted in 15 per group (Cosgarea et al. 2018). Considering possible dropouts, 20 participants will be included per group. Randomization will not be performed since the purpose was to compare the effects of NSPT in patients with and without RA. The clinical investigator who records periodontal parameters will be calibrated for repeated measurements before patient inclusion (Kappa value was ≥0.80 for PAL and PD). Continuous variables will be presented as the mean and 95% confidence interval (CI) or median \[interquartile range\] when appropriate. Change in biochemical markers (CRP, RF, ACPAs) and periodontal parameters (PAL, PD, BOP, microbial counts) will be expressed as the delta (∆) from baseline to 3 months after intervention. Differences in means will be determined by the student t test for paired and unpaired samples or non-parametric tests when appropriate. Categorical variables will be presented as frequencies (%) and analyzed in contingency tables and X2. Logistic regression analysis for categorical variables and linear models will be used to test for associations and the odds ratio with 95%CI will be calculated. The primary analysis will be performed as intention to treat and then compared to per-protocol analysis results. The level of statistical significance will be set at 5% (P≤0,05).
Participants will undergo Kurbo program, a Mobile health application, for more detailed dietary and physical activity recommendations and implementation of behavioural changes. The patient's progress will be reviewed by the nurse clinician at one month post intervention to determine whether the BMI percentile has shown a reduction through the Kurbo Program. Patients that declined Kurbo intervention, has a BMI of more than 99th percentile or continue to have increase in their BMI percentile in Kurbo program, will be offered the high risk weight management clinic appointment for a more detailed multidisciplinary evaluation for targeted intervention. Patients that are able to engage with Kurbo intervention and showed a decrease in BMI percentile over 4 sessions of Kurbo will be offered the low risk weight management clinic (WMC). There will be a month 3 and month 6 visit for study measurements in this study.
Each scored oxybutynin chloride tablet, USP contains 5 mg of oxybutynin chloride. Chemically, oxybutynin chloride, USP is d,l (racemic) 4-diethylamino-2-butynyl phenylcyclohexylglycolate hydrochloride. The empirical formula of oxybutynin chloride is C22H31NO3 ∙ HCl. The structural formula appears below:

Oxybutynin chloride, USP is a white crystalline solid with a molecular weight of 393.9. It is readily soluble in water and acids, but relatively insoluble in alkalis.

Oxybutynin chloride tablets, USP also contain anhydrous lactose, calcium stearate, and microcrystalline cellulose.

Oxybutynin chloride tablets, USP are for oral administration.

Therapeutic Category: Antispasmodic, anticholinergic.
Systems and methods are disclosed for sensor-based location determination and dynamic routing. In one implementation, a first request corresponding to a first location identifier is received. The first request is assigned based on a location of a first device. A second location identifier is received in conjunction with a fulfillment of the first request and based on a perception of one or more access points by one or more sensors of the first device. The second location identifier is associated with the first location identifier. A second request corresponding to the first location identifier is received. The second request is assigned to the second device with respect to the second location identifier based on input(s) originating from sensor(s) of a second device and an association, with respect to the fulfillment of the first request, of the second location identifier with the first location identifier.
FIELD: biochemistry, chemistry of proteins. SUBSTANCE: invention relates to protein characterizing the following properties: (a) molecular mass about 60 kDa under reducing conditions, about 60 kDa and 120 kDa under nonreducing conditions at electrophoresis in polyacrylamide gel in the presence of sodium dodecyl sulfate (SDS-PAGE); (b) high affinity to cation-exchange column and column with heparin; (c) biological activity of inhibition of differentiation and/or maturation of osteoclasts being this activity is decreased in heating at 70 C for 10 min or at 56 C for 30 min and indicated activity is lost in heating at 90 C for 10 min; (d) internal amino acid sequences presented in SEQ ID NO : 1, 2 and 3; and (e) optionally having N-terminal amino acid sequences presented in SEQ ID NO : 7. Invention relates to method of such proteins by culturing human fibroblasts, purification of protein by combination of column ion-exchange chromatography, affinity column chromatography and column chromatography with reversed phase. Invention relates also to proteins with amino acid sequence presented in SEQ ID NO : 4, cDNA encoding amino acid presented in SEQ ID NO : 4; cDNA with nucleotide sequence presented in SEQ ID NO : 6 encoding protein OCIF with signal peptide having amino acid presented in SEQ ID NO : 5; protein expressed from cDNA encoding amino acid sequence presented in SEQ ID NO : 4; protein with biological activity of inhibition of differentiation and/or maturation of osteoclasts that is obtained as amino acid sequence expressed by cDNA having at least 80% of identity with amino acid sequence presented in SEQ ID NO : 4; method of preparing protein inhibiting development of osteoclasts by methods of genetic engineering and using cDNA encoding amino acid sequence presented in SEQ ID NO : 4: (a) molecular mass about 60 kDa under reducing conditions and about 60 kDa and 120 kDa under nonreducing conditions at electrophoresis in polyacrylamide gel in the presence of sodium dodecyl sulfate (SDS-PAGE); (b) high affinity to cation-exchange column and to column with heparin; (c) inhibitory activity of differentiation and/or maturation of osteoclasts that is decreased at heating at 70 C for 10 min or at 56 C for 30 min being indicated activity is lost at heating at 90 C for 10 min; (d) internal amino acid sequence presented in SEQ ID NO : 1-3; cDNA encoding protein OCIF or its variants; genome DNA with nucleotide sequence presented in SEQ N : 104 or 105; polyclonal antibody with specific affinity raised to OCIF; monoclonal antibody with specificity to OCIF obtained by hybridoma technology using OCIF as antigen and characterizing the following properties: molecular mass 150 000 Da; method of determination of concentration of protein OCIF. EFFECT: improved method of proteins preparing. 19 cl, 16 tbl, 15 dwg, 26 ex
BACKGROUND: This study aimed to uncover the changing prevalence of obesity and its association with hypertension across socioeconomic gradients in rural southwest China.
METHODS: Data were collected from two cross-sectional health interviews and surveys from 2011 to 2021 among individuals aged ≥ 35 years in rural China. Each participant's height, weight, waist circumference, and blood pressure were measured. The overall prevalence of obesity, central obesity, and hypertension was directly standardized by age based on the total population of the two surveys. Multivariate logistic regression was used to analyze the association between obesity and prevalence of hypertension and an individual socioeconomic position (SEP) index was constructed using principal component analysis.
RESULTS: From 2011 to 2021, the prevalence of obesity, central obesity, and hypertension increased substantially, from 5.9%, 50.2%, and 26.1-12.1%, 58.0%, and 40.4% (P < 0.01), respectively. These increasing rates existed in all subcategories, including sex, age, ethnicity, education, annual household income, access to medical services, and SEP (P < 0.05). In both 2011 and 2021, lower education level and poor access to medical services correlated with higher prevalence of central obesity, while higher SEP correlated with higher prevalence of obesity and central obesity (P < 0.01). Prevalence of obesity was higher in the Han ethnicity participants and individuals with poor access to medical services than in their counterparts (P < 0.01). Whereas the prevalence of central obesity was lower in Han participants than in ethnic minority participants in 2011 (P < 0.01), this trend reversed in 2021 (P < 0.01). A positive relationship between annual household income and prevalence of obesity and central obesity was only found in 2021 (P < 0.01). Obese and centrally obese participants were more likely to be hypertensive in both survey years (P < 0.01).
CONCLUSIONS: Future interventions to prevent and manage obesity in rural China should give increased attention to high income, less educated, poor access to medical services, and high SEP individuals. The implementation of these obesity interventions would also help reduce the prevalence of hypertension.
In a controlled study, 940 patients with locally advanced SCCHN were randomized 1:1 to receive either ERBITUX in combination with radiation therapy and cisplatin or radiation therapy and cisplatin alone. The addition of ERBITUX resulted in an increase in the incidence of Grade 3 and 4 mucositis, radiation recall syndrome, acneiform rash, cardiac events, and electrolyte disturbances compared to radiation and cisplatin alone. Adverse reactions with fatal outcome were reported in 4% of patients in the ERBITUX combination arm and 3% in the control arm. In the ERBITUX arm, 2% experienced myocardial ischemia compared to 0.9% in the control arm. The main efficacy outcome of the study was progression-free survival (PFS). The addition of ERBITUX to radiation and cisplatin did not improve PFS. ERBITUX is not indicated for the treatment of SCCHN in combination with radiation and cisplatin.